A phase III study comparing nivolumab with nivolumab plus docetaxel in patients with previously treated advanced non-small-cell lung cancer: a randomized phase II/III trial(TORG1630)

Next Previous
Trial Profile

A phase III study comparing nivolumab with nivolumab plus docetaxel in patients with previously treated advanced non-small-cell lung cancer: a randomized phase II/III trial(TORG1630)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TORG1630

    • Most Recent Events

    • 11 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 23 Apr 2017 Planned initiation date changed from 1 Jul 2017 to 1 Aug 2017.
    • 03 Feb 2017 Trial phase changed from III to II/III. Primary endpoints amended. Trial focus changed. (TU to TU, AR).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top